We're building  curative gene therapies for life threatening kidney diseases.

Launch your product — and savor the momentum.

Get the App
research and advisors from

Nephrogen is a seed-stage biotech company developing curative gene therapies for kidney diseases.

Our initial indication is autosomal dominant polycystic kidney disease (ADPKD), which affects 600,000 Americans and has no cure or effective treatment. Tolvaptan (JYNARQUE®) is the only FDA approved drug for ADPKD, costs $13K for a 28-day supply, and must be taken twice daily for decades for maximum benefit. Our solution aims to halt ADPKD from the onset and provide an outright cure for the disease.

We're boldly committed to reimagining therapeutics for life threatening kidney disease. Our broad patent portfolio will allow us to rapidly translate our technologies into foundational partnerships and transformative treatments.

Our technology

Curative gene therapies for kidney diseases.

Our groundbreaking platform combines the power of CRISPR-Cas genome editing with the latest advances in nucleic delivery, such as adeno-associated viruses (AAVs), to create a solution that targets kidney disease at the source.

Our novel technology has three primary components:

Maximum therapeutic effect

We have developed a non-invasive method for delivering gene therapy locally to the kidney using breakthrough filed IP.

Precision therapy delivery

We have engineered novel AAV viruses via directed evolution that target the kidney with 100x better efficiency than existing AAVs

Personalized approach

We are pursuing several unique gene targets in PKD1, the gene that causes, autosomal dominant polycystic kidney disease (ADPKD).

Rapid drug discovery

Nephrogen's drug discovery platform leverages innovations in computer vision and high-throughput screening (HTS) to find new small molecule drugs for other cystic kidney diseases, including and nephronophthisis.

Our team


Demetri Maxim
Chief Executive Officer
Vivek Bhalla, MD
Chief Medical Advisor
Maggie Thompson
Research Associate
Fernando Gomez Garcia
Biomedical Research Intern
Najani Johnson
Computational Biology Intern
Miriam Rivera Moreno
Biomedical Research Intern


George Church, PhD
Professor of Genetics
Scientific Advisor
Avnesh Thakor, MD, PhD
Associate Professor of Radiology, Stanford University
Scientific Advisor
Mark Kay, MD, PhD
Professor of Genetics, Stanford University
Scientific Advisor
Terry Watnick, MD
Director, Polycystic Kidney Disease Research Resource Consortium
Scientific Advisor
Vishal Patel, MD
Professor of Medicine/Nephrology
Scientific Advisor
Ron Perrone, MD
Professor of Nephrology, Tufts University School of Medicine
Scientific Advisor
Shelley Amster
Founder, ShelleyCO
Business Advisor
Jan Liphardt, PhD
Associate Professor of Bioengineering, Stanford University
Scientific Advisor


news & publication

Browse our latest media